Grail cancer-detection blood test reaches first major US regulatory review
Grail’s blood test, designed to look for signs of multiple cancers in people without symptoms, is facing its first major regulatory hurdle in the United States. The FDA review could become an important test of the approach, but the supplied report gives no decision or timeline.
A blood test developed by Grail to look for signs of multiple cancers in healthy people is facing its first major regulatory hurdle in the United States, according to ABC News US. The test is designed to search for indications of cancer in people who do not necessarily have symptoms. Its review by the US Food and Drug Administration represents the first major US regulatory challenge identified in the supplied report.
The report describes the review as high-stakes for Grail, but does not provide details about the test’s performance, the cancers it is intended to detect or the evidence submitted to regulators. It also does not say whether the FDA has approved, rejected or requested changes to the test. No decision date, review timetable or potential conditions of use are included in the available material.
The FDA process will determine the next regulatory step for the blood test, but the source does not establish what that outcome will be. It says only that Grail’s test is entering a significant US review as the company seeks to use blood-based screening to identify signs of multiple cancers in healthy people.
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.